Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB-02: tucatinib or placebo plus T-DM1 in HER2-positive metastatic or unresectable locally advanced breast cancer
MOH_2020-10-05_009382Phase 3Not yet recruiting
- Sponsor
- Seagen
- Start
- Jun 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tucatinib and trastuzumab emtansine in breast cancer (2 arms), sponsored by Seagen. Primary endpoint: Progression-free survival. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
tucatinibtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-10-05_009382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-05_009382.